Extrasynaptic ␥-aminobutyric acid type A receptors (GABA A Rs), which contribute generalized inhibitory tone to the mammalian brain, are major targets for general anesthetics. To identify anesthetic binding sites in an extrasynaptic GABA A R, we photolabeled human ␣4␤3␦ GABA A Rs purified in detergent with [ 3 H]azietomidate and a barbiturate, [ 3 H]R-mTFD-MPAB, photoreactive anesthetics that bind with high selectivity to distinct but homologous intersubunit binding sites in the transmembrane domain of synaptic ␣1␤3␥2 GABA A Rs. Based upon 3 H incorporation into receptor subunits resolved by SDS-PAGE, there was etomidate-inhibitable labeling by [ 3 H]azietomidate in the ␣4 and ␤3 subunits and barbiturate-inhibitable labeling by [ 3 H]R-mTFD-MPAB in the ␤3 subunit. These sites did not bind the anesthetic steroid alphaxalone, which enhanced photolabeling, or DS-2, a ␦ subunit-selective positive allosteric modulator, which neither enhanced nor inhibited photolabeling. The amino acids labeled by [ 3 H]azietomidate or [ 3 H]R-mTFD-MPAB were identified by N-terminal sequencing of fragments isolated by HPLC fractionation of enzymatically digested subunits. No evidence was found for a ␦ subunit contribution to an anesthetic binding site. [ 3 H]azietomidate photolabeling of ␤3Met-286 in ␤M3 and ␣4Met-269 in ␣M1 that was inhibited by etomidate but not by R-mTFD-MPAB established that etomidate binds to a site at the ␤3 ؉ -␣4 ؊ interface equivalent to its site in ␣1␤3␥2 GABA A Rs. [ 3 H]Azietomidate and [ 3 H]R-mTFD-MPAB photolabeling of ␤3Met-227 in ␤M1 established that these anesthetics also bind to a homologous site, most likely at the ␤3 ؉ -␤3 ؊ interface, which suggests a subunit arrangement of ␤3␣4␤3␦␤3.
␥-Aminobutyric acid type A receptors (GABA A Rs) 2 are the major inhibitory neurotransmitter receptors in the mammalian brain. They are members of the pentameric ligand-gated ion channel superfamily that consists of five homologous subunits, each of which has a large extracellular domain, a transmembrane domain of four transmembrane helices (M1-M4), and an intracellular domain connecting the third and fourth transmembrane helices. GABA A Rs, which are the target of many drugs, among them benzodiazepines and general anesthetics, are heteropentamers, and drug action often depends on the subunit composition. For example, at synaptic receptors, which commonly have a subunit composition of (␣)2(␤)2␥, arranged ␤␣␤␣␥ counterclockwise when viewed from the synaptic or extracellular side of the receptor, benzodiazepines act in the extracellular domain between ␣ ϩ -␥ Ϫ subunits at a site homologous to the GABA binding sites at the two ␤ ϩ -␣ Ϫ subunit interfaces ( Fig. 1) (1-3) .
General anesthetics have long been known to bind to sites in the transmembrane domains of pentameric ligand-gated ion channels (reviewed in Refs. 4 -7) . Photolabeling of endogenous and heterologous GABA A Rs by [ 3 H]azietomidate located the etomidate binding site in the two ␤ ϩ -␣ Ϫ subunit interfaces (8, 9) , 50 Å from the GABA site and at a position later shown to overlap with the five ivermectin sites in the crystal structure of the homopentameric glutamate-gated chloride channel (GluCl) (10) . More recently, a photoreactive, anesthetic barbiturate, R-mTFD-MPAB, has been shown to bind to sites in the ␥ ϩ -␤ Ϫ and ␣ ϩ -␤ Ϫ subunit interfaces homologous to the etomidate binding sites, introducing the concept of subtype-dependent action of general anesthetics (11) . Whereas etomidate and R-mTFD-MPAB bind with high selectivity to their sites, propofol, pentobarbital, and other barbiturates bind with much less selectivity to these two classes of sites.
The in vivo mechanism of action of etomidate has been firmly linked to the GABA A R. Heterologously expressed GABA A Rs that have an N256M mutation on the M2 helix of the ␤3 subunit (␤ ϩ surface of the interface) are relatively insensitive to etomidate (12) , and sleep times in knock-in mice bearing the same mutation are much shorter than in wild-type mice (13) .
Azietomidate causes normal anesthesia in wild-type mice with the same potency as etomidate, and its action is similarly attenuated in the knock-in mouse (14) . R-mTFD-MPAB also causes general anesthesia in mice and is equally potent in wild-type and N256M knock-in mice (15) , consistent with the location of its binding sites at the ␤ Ϫ subunit interfaces.
The contrasting subunit-selective actions of these two agents raise questions about the mechanism of general anesthesia itself, because there are 19 known GABA subunits, and which of the possible combinations occur in vivo is not yet fully defined. The state of anesthesia involves many behavioral components (16) , so subunit-selective general anesthetics might be associated with specific subsets of the behavioral impairments experienced during anesthesia (17) . Of particular interest are the relative contributions of phasic (synaptic) and tonic (extrasynaptic) inhibition actions (18, 19) . The focus of this study is on the extrasynaptic ␣4␤3␦ GABA A Rs that are sensitive to endogenous neurosteroids and general anesthetics at concentrations lower than necessary to potentiate inhibitory postsynaptic currents (20 -24) . Expression studies in fibroblasts and oocytes establish that multiple combinations of ␣4, ␤, and ␦ subunits can combine to form functional receptors, which results in alternative subunit interfaces (25) (26) (27) (28) (29) (30) (31) .
In this work, we photolabeled detergent-solubilized, purified heterologous ␣4␤3␦ GABA A Rs with [ 3 H]azietomidate and [ 3 H]R-mTFD-MPAB. Two distinct high affinity anesthetic sites were identified: 1) [ 3 H]azietomidate photolabeling established that azietomidate and etomidate bind to a ␤3 ϩ -␣4 Ϫ interface site that does not bind R-mTFD-MPAB with high affinity; and 2) [ 3 H]azietomidate and [ 3 H]R-mTFD-MPAB share a common binding site with etomidate at a ␤3 Ϫ subunit interface. DS2, a positive allosteric modulator selective for GABA A Rs containing a ␦ subunit (32), did not bind to these sites.
Results
Biochemical Characterization of the ␣4␤3␦ GABA A R-Comparison of [ 3 H]muscimol binding to ␣4␤3␦ GABA A R in membranes and after purification in asolectin/CHAPS established that positive allosteric modulation was retained by etomidate and by DS2, a positive allosteric modulator selective for GABA A Rs containing the ␦ subunit (32) ( Table 1) . In contrast to ␣1␤3␥2 GABA A Rs, which bound [ 3 H]muscimol with similar affinity in membrane-bound (K eq ϭ 50 nM) and purified (K eq ϭ 80 nM) states (33) , [ 3 H]muscimol bound to ␣4␤3␦ GABA A Rs in membranes (K eq ϭ 13 nM) with higher affinity than after purification in CHAPS/asolectin (K eq ϭ 90 nM). After purification, etomidate (10 M) and DS2 (30 M) increased the specific binding of 2 nM [ 3 H]muscimol by ϳ30%.
When samples of purified human ␣4␤3␦ GABA A R were fractionated by SDS-PAGE and visualized by Coomassie Blue stain, bands were readily visualized at 78 and 58 kDa, along with 7) , and subunits were resolved by SDS-PAGE. After Coomassie Blue staining (CB, representative image in lane 1), the gel was prepared for fluorography (lanes 2 -7) . Migration positions of molecular mass standards (in kDa) are denoted to the left of lane 1. fainter bands at 72, 62, and 54 kDa (Fig. 2, lane 1) . When extracted materials from in-gel tryptic digests of these bands were characterized by LC/MS/MS ( Table 2) , fragments of the GABA A R ␣4 subunit were most enriched in the 72 kDa band, consistent with the expected mobility of the mature subunit (58 kDa ϩ 3 N-linked glycosylations). Fragments from the ␤3 subunit were concentrated in the 62 and 58 kDa bands, as found for ␤3 subunit from expressed ␣1␤3␥2 GABA A Rs (11) . Fragments from the ␦ subunit were broadly distributed in the 62, 58, and 54 kDa bands, with ␣4 subunit fragments also recovered from the 54 kDa band. However, in contrast to the recovery of ␣4 subunit fragments from the 72 kDa gel band, for the 54 kDa band, no fragments were recovered from the ␣4 cytoplasmic domain beginning about 30 amino acids after the end of the M3 helix (data not shown). This result suggests that the 54 kDa band contains an N-terminal fragment of the ␣4 subunit containing the M1-M3 helices that was probably produced by proteolytic cleavage during receptor purification. The major component in the 78 kDa band was identified as the chaperone heat shock 70-kDa protein 1A (HSP70-1). When material eluted from the 72 kDa band was characterized by Edman degradation, the primary sequence identified (XXLNXXPGQNQXXXXL . . . ) matched a region near the predicted N terminus of the human ␣4 GABA A R subunit (VCL-NESPGQNQKEEKL . . . ). Multiple amino acids were detected at similar levels at each cycle of Edman degradation of the 62and 58-kDa samples, which precluded de novo identification of the subunits present. Sequence analysis of material from the 54 kDa band identified a primary sequence (XNDIXXYKXD . . . ) matching the N terminus region of the FLAG-tagged human ␦ GABA A R subunit sequence (MNDIGDYKDDDDK . . . , with the underline denoting the FLAG peptide sequence). The N termini of the ␣4 and ␦ subunits identified by Edman degradation are those predicted to be the N termini of the mature subunits by the signal sequence cleavage site prediction program P-signal (34) . No N-terminal sequence was detected from the 78-kDa material, consistent with the fact that the N-terminal alanine of 70-kDa heat shock protein is acetylated (35) , preventing Edman degradation.
Labeling Human ␣4␤3␦ GABA A R with Photoreactive Anesthetics-␣4␤3␦ GABA A Rs were photolabeled at anesthetic concentrations with [ 3 H]azietomidate or [ 3 H]R-mTFD-MPAB in the absence or presence of etomidate at 1 mM or non-radioactive R-mTFD-MPAB at 60 M, concentrations at which they each bind selectively to the ␤ ϩ or ␤ Ϫ intersubunit sites in ␣1␤3␥2 GABA A Rs (11) . When 3 H incorporation was determined by fluorography after SDS-PAGE ( Fig. 2, lanes 2-7) , 3 H incorporation was highest in the 58/62 kDa gel region for both photoreactive anesthetics. The 72 kDa band (␣4) was labeled prominently only by [ 3 H]azietomidate, and that photolabeling was inhibitable by etomidate but not by R-mTFD-MPAB.
[ 3 H]Azietomidate photolabeling in the 54/58/62 kDa gel bands was inhibited to a greater extent by etomidate than by R-mTFD-MPAB, and, conversely, [ 3 H]R-mTFD-MPAB photolabeling of 58/62 kDa gel bands was inhibited to a greater extent by R-mTFD-MPAB than by etomidate. These findings suggested that 1) there is an etomidate/azietomidate binding site associated with the ␣4 subunit that does not bind R-mTFD-MPAB with high affinity; 2) azietomidate, etomidate, and R-mTFD-MPAB share a common binding site associated with the 58/62 kDa gel band; and 3) there may be an R-mTFD-MPAB binding site associated with the 58/62 kDa gel band that does not bind etomidate.
To further characterize the pharmacological specificity of [ 3 H]azietomidate and [ 3 H]R-mTFD-MPAB incorporation at the subunit level, photolabelings were performed on an analytical scale in the presence of various concentrations of etomidate, R-mTFD-MPAB, the neuroactive steroid alphaxalone, or DS2, with 3 H incorporation into the gel bands quantified by liquid scintillation counting ( Fig. 3 ). Etomidate inhibited [ 3 H]azietomidate photoincorporation into the 72 kDa (␣4) and 58/62 kDa bands with IC 50 values of ϳ15 M, with high con- 
LC/MS/MS identification of major peptides in ␣4␤3␦ GABA A R SDS-polyacrylamide gel bands
Shown are search results from a Homo sapiens protein database: HSPA1A, heat shock 70-kDa protein 1A/1B; PRMT5, arginine N-methyltransferase 5; GABRA4, GABA A R ␣4 subunit; LMNB1, lamin-B1; GABRD, GABA A R ␦ subunit; IGF2BP1, insulin-like growth factor 2 mRNA-binding protein 1; ABCD3, ATP-binding cassette subfamily D member 3; GABRB3, GABA A R ␤3 subunit; TUBA1A, tubulin ␣-1A chain; TUBB2A, tubulin ␤-2A chain; DDX47, probable ATP-dependent RNA helicase DDX47. Fig. 4 ). For both photoreactive anesthetics, the digests of the 58/62 kDa band (␤3 and ␦ subunits) contained peaks of 3 H in hydrophobic fractions (ϳ55 and 70% organic solvent) where fragments beginning at the N termini of the ␤M3 and ␤M1 helices are known to elute (36) . For the 72 kDa band (␣4) labeled by [ 3 H]azietomidate, the 3 H eluted in two peaks, a broad hydrophobic peak (55% organic solvent), which for digests of ␣1 subunits contains fragments beginning at the N termini of the M1 and M3 helices, and a peak at 40% organic solvent, where fragments from the ␣1 subunit extracellular domain elute (36) . For the 54 kDa band, for each drug, there were peaks of 3 H at 40, 55, and 70% organic solvent, corresponding to the peaks seen in either of the higher molecular weight gel bands.
Gel band
Etomidate Inhibits [ 3 H]Azietomidate Photolabeling of ␣4Met-269 (␣M1), ␤3Met-227 (␤M1), and ␤3Met-286 (␤M3)-Aliquots were sequenced of unfractionated EndoLys-C digests from the 72 and 58/62 kDa gel bands from GABA A Rs photolabeled with [ 3 H]azietomidate in the absence and presence of non-radioactive etomidate ( Fig. 5 ). For the 72 kDa band, there was a major peak of etomidate-inhibitable 3 H release in cycle 14 ( Fig. 5A ). For the digest from the 58/62 kDa band ( Fig. 5B ), there were peaks of etomidate-inhibitable 3 H release in cycles 7 and 12 (pharmacologically specific photolabeling) and peaks of 3 H release in cycles 3 and 19 that were not inhibited by etomidate (nonspecific labeling). The 72 kDa gel band digest will contain all possible ␣4 subunit proteolytic fragments, including fragments beginning near the N termini of the M1-M4 helices. For the 58/62 kDa band, digests will include fragments beginning near the N termini of the M1, M3, and M4 helices of the ␤3 and ␦ subunits ( Fig. 5C ). However, the etomidate-inhibitable peak of 3 H release in cycle 14 for the 72 kDa band digest occurs in the cycle predicted to contain ␣4Met-269, the residue homologous to ␣1Met-236 in the ␣1 subunit M1 helix that was photolabeled by [ 3 H]azietomidate (8, 9, 11) . Similarly, the peaks of etomidate-inhibitable 3 H release in cycles 7 and 12 for the 58/62 kDa band digest occur in the sequencing cycles that will contain ␤3Met-286 in ␤M3 and ␤3Met-227 in ␤M1, respectively, residues also photolabeled by [ 3 H]azietomidate in ␣1␤3 or ␣1␤3␥2 GABA A R (9, 11), as well as the residues from ␦M3 (␦Trp-315 and ␦Phe-320). The peaks of release in cycles 3 and 19 that were not inhibited by etomidate occur in cycles that contain Asp or Glu near the N and C termini of the ␤3 and ␦ subunit M3 helices.
R-mTFD-MPAB Inhibits [ 3 H]Azietomidate Photolabeling of ␤3Met-227 but Not ␣4Met-269 -To confirm that [ 3 H]azietomidate photolabeled ␣4Met-269 and ␤3Met-227, samples were sequenced after rpHPLC fractionation of EndoLys-C digests of material from the 72, 58/62, and 54 kDa gel bands. To determine whether R-mTFD-MPAB also inhibited photolabeling of these residues, receptors were photolabeled in the absence or the presence of 20 M R-mTFD-MPAB, a concentration sufficient to occupy ϳ90% of its high affinity binding sites based upon the inhibition of photolabeling at the subunit level ( Fig. 3 ). When fractions from the 58/62 kDa band were sequenced that contained the fragment beginning at ␤3Arg-216 at ϳ15 pmol ( Fig. 6A ), the peak of 3 H release in cycle 12 confirmed labeling of ␤3Met-227 (220 cpm/pmol), and R-mTFD-MPAB inhibited that labeling by ϳ80%. When fractions from the 72 kDa (␣4) gel band were sequenced ( Fig. 6B ) that contained the fragment beginning at ␣4Met-256 (1 pmol), there was a single peak of 3 H release in cycle 14, consistent with photolabeling of ␣4Met-269 in ␣4M1 at 230 cpm/pmol in the absence or presence of R-mTFD-MPAB.
R-mTFD-MPAB Does Not Inhibit [ 3 H]Azietomidate Photolabeling of ␤3Met-286 -To determine whether [ 3 H]azietomidate was photolabeling amino acids in ␤M3 and/or ␦M3, we sequenced rpHPLC fractions from EndoLys-C digests of the 58/62 kDa gel band enriched in ␤M3 and from the 54 kDa gel band enriched in ␦M3. When fractions from the 58/62 kDa gel band were sequenced containing fragments beginning at ␤3Ala-280 (ϳ6 pmol) and at ␦Ala-309 (4 pmol) ( Fig. 7A ), there was a peak of 3 H release in cycle 7 (280 cpm), which R-mTFD-MPAB inhibited by Ͻ15%. In contrast, when fractions from the 54 kDa gel band were sequenced containing fragments beginning at ␤3Ala-280 (1 pmol) and at ␦Ala-309 (2 pmol), the peak of 3 H release in cycle 7 was 25 cpm (Fig. 7B ). Because the 3 H ␣4␤3␦ GABA A R General Anesthetic Binding Sites DECEMBER 16, 2016 • VOLUME 291 • NUMBER 51 releases in cycle 7 correlated well with the amount of the ␤3Ala-280 fragment but not with the amount of the ␦M3 fragment, the peak of 3 H release in cycle 7 indicated photolabeling of ␤3Met-286 (130 cpm/pmol) rather than ␦Trp-315. That [ 3 H]azietomidate labeling of ␤3Met-286 (␤M3) and ␣4Met-269 (␣M1) was inhibited by etomidate ( Fig. 5 ), but not by R-mTFD-MPAB, indicates that etomidate and azietomidate bind to a site at the ␤3 ϩ -␣4 Ϫ interface that does not bind R-mTFD-MPAB with high affinity and is homologous to their binding site at the ␤3-␣1 interface. (Fig. 8) . When fractions were sequenced containing the fragment beginning at ␤3Arg-216 (15 pmol), the single peak of 3 H release in cycle 12 indicated photolabeling of ␤3Met-227 (160 cpm/ pmol) that R-mTFD-MPAB inhibited by Ͼ95% (Fig. 8A) . When rpHPLC fractions from the 58/62 kDa digest were sequenced that contained the M3 fragments, there were prominent peaks of 3 H release in cycles 7 (50 cpm), 9 (90 cpm), and 10 (75 cpm) ( Fig. 8B) , whereas for the 54 kDa band, peaks of 3 H release were Ͻ7 cpm (Fig. 8C) . As for labeling by [ 3 H]azietomidate, the peaks of 3 H release correlated well with the amounts of the ␤3Ala-280 fragment (Fig. 8, B (8 pmol) and C (1 pmol)) but not the ␦Ala-309 fragment (Fig. 8, B (4 pmol) and C (2 pmol)). The peaks of 3 H release in cycles 7 and 10 indicate photolabeling in ␤3M3 of ␤3Met-286 (16 cpm/pmol), ␤3Cys-288 (30 cpm/ pmol), and ␤3Phe-289 (34 cpm/pmol). Based upon the calculated efficiencies of photolabeling (cpm/pmol) in the absence and presence of 60 M R-mTFD-MPAB (see the legend to Fig.  8 ), the labeling of ␤3Met-286 and ␤3Phe-289 was inhibited by Ͼ90%, whereas photolabeling of ␤Cys-288 was inhibited by Յ50%. A, the primary sequence began at ␤3Ala-280 (I 0 ϭ 6 pmol; Ⅺ, residues unique to ␤3M3) with the secondary sequence beginning at ␦Ala-309 (I 0 ϭ 4 pmol; ƒ, residues unique to ␦M3). The detected pmol of residues common to both ␤3M3 and ␦M3 (छ) were not used for the repetitive yield fits. The peak of 3 H release in cycle 7, if originating from ␤3M3, indicated labeling of ␤3Met-286 at 130 cpm/pmol, and R-mTFD-MPAB inhibited that labeling by Ͻ15%. B, the primary sequence began at ␦Ala-309 (I 0 ϭ 2 pmol; ƒ, residues unique to ␦M3) with the secondary sequence beginning at ␤3Ala-280 (I 0 ϭ 1 pmol; Ⅺ, residues unique to ␦M3). The peaks of 3 , and the peak of 3 H release in cycle 12 indicated photolabeling of ␤3Met-227 (160 cpm/pmol) that R-mTFD-MPAB inhibited by Ͼ95%. B, the primary sequence began at ␤3Ala-280 (␤3M3) (Ⅺ, residues unique to ␤3M3; I 0 ϭ 8/4 pmol, without/with R-mTFD-MPAB) with the secondary sequence beginning at ␦Ala-309 (ƒ, residues unique to ␦M3; I 0 ϭ 4/2 pmol, without/ with R-mTFD-MPAB). The detected pmol of residues common to ␤3M3 and ␦M3 (छ) were not used for the repetitive yield fits. The 3 H release in cycles 7 and 10, if originating from ␤3M3, indicated labeling of ␤3Met-286 and ␤3Phe-289 at 16 and 34 cpm/pmol, respectively, with Ͼ90% inhibition by R-mTFD-MPAB. The 3 H release in cycle 9 indicates photolabeling of ␤3Cys-288 (31/17 cpm/pmol without/with R-mTFD-MPAB) and/or ␦Cys-317 (84/40 cpm/pmol without/with R-mTFD-MPAB). C, the primary sequence began at ␦Ala-309 (ƒ, residues unique to ␦M3; I 0 ϭ 2/3 pmol, without/with R-mTFD-MPAB) with the secondary sequence beginning at ␤3Ala-280 (Ⅺ, residues unique to ␤3M3, I 0 ϭ 1 pmol, both conditions). In B and C, the peaks of 3 H release in cycles 7, 9, and 10 correlate well with the amounts of the ␤3Ala-280 fragment (B, 8 pmol; C, 1 pmol) but not with those of the ␦Ala-309 fragment (B, 4 pmol; C, 2 pmol).
Discussion
In this report, we provide a first characterization of the locations of anesthetic binding sites in a GABA A R subtype expressed extrasynaptically in the CNS. We photolabeled purified human ␣4␤3␦ GABA A Rs with [ 3 H]azietomidate and [ 3 H]R-mTFD-MPAB, photoreactive anesthetics that have been used previously to identify two homologous but pharmacologically distinct classes of anesthetic binding sites in ␣1␤3␥2 GABA A Rs (11) . Based upon the identification of photolabeled amino acids and the results of competition photolabeling assays carried out at the level of intact subunits, we demonstrate that etomidate, but not R-mTFD-MPAB, binds with high affinity to a site at the ␤ ϩ -␣ Ϫ subunit interface in ␣4␤3␦ GABA A Rs that is equivalent to its binding site in ␣1␤3␥2 GABA A Rs. In contrast to ␣1␤3␥2 GABA A Rs, which bind R-mTFD-MPAB, but not etomidate, with high affinity to sites at the ␣ ϩ /␥ ϩ -␤ Ϫ interfaces in proximity to ␤3Met-227 in ␤M1, we find that etomidate as well as R-mTFD-MPAB bind with high affinity to a site in ␣4␤3␦ GABA A Rs containing ␤3Met-227. As discussed below, this site is most likely to be at a ␤ ϩ -␤ Ϫ subunit interface. The sites identified by photolabeling with [ 3 H]azietomidate and [ 3 H]R-mTFD-MPAB are distinct from the binding sites for alphaxalone, an anesthetic steroid, or DS-2, a ␦ subunit-selective positive allosteric modulator (32) , because neither drug inhibited photolabeling.
␣4␤3␦ GABA A R Composition-Based upon mass spectrometry and Edman degradation, the affinity-purified ␣4␤3␦ GABA A Rs used in this work contain ␣4 and ␤3 subunits as well as the ␦ subunit, whose presence is assured because the FLAG epitope used for purification is attached near the ␦ subunit N terminus. However, we do not know whether the preparation is characterized by a single dominant subunit composition. Whereas receptors having a ␤3␣4␤3␣4␦ subunit arrangement (counterclockwise when viewed from the extracellular side) with two ␤3 ϩ -␣4 Ϫ interfaces containing the agonist sites and a ␦ subunit replacing the ␥ subunit have been reported to be strongly favored in transiently transfected HEK cells (27, 28, 37) , other studies indicate that subunit stoichiometry can be variable and dependent upon the subunit cDNA transfection ratios (26) . Also, studies using concatenated subunits provide evidence that the ␦ subunit can assume multiple positions in a receptor pentamer and can contribute to a ␤ ϩ -␦ Ϫ agonist binding site (25, 27, 30) .
In the absence of independent definition of the subunit composition and arrangement in our purified ␣4␤3␦ GABA A Rs, consideration of our photolabeling results suggests a ␤3␣4␤3␦␤3 or ␤3␦␤3␣4␤3 organization for the stably transfected cell line used in our studies. We favor these stoichiometries because 1) they have a ␤3-␤3 interface required for the shared azietomidate/etomidate/R-mTFD-MPAB binding site, and 2) they have three ␤3 subunits to every one ␣4 subunit, consistent with the similar levels of [ 3 H]azietomidate incorporation (cpm/pmol) at the amino acid level in the ␤3 and ␣4 subunits (Fig. 6) in the presence of a higher level of 3 H incorporation in the ␤3 gel band than in the ␣4 band (Fig. 2) . However, a ␤2␣4␦␣4␤2 pentameric concatemer, containing a ␤-␤ interface, also forms a functional receptor (30) .
An Etomidate Binding Site at the ␤3 ϩ -␣4 Ϫ Interface-[ 3 H]Azietomidate photolabeled ␤3Met-286 in ␤3M3 (␤3 ϩ side of an interface) and ␣4Met-269 in ␣4M1 (␣4 Ϫ side), with etomidate inhibiting labeling by Ͼ90% and R-mTFD-MPAB by Ͻ15%. Because [ 3 H]azietomidate also photolabeled ␤3Met-286 in ␣1␤3␥2 GABA A Rs and ␣4Met-269 is homologous to ␣1Met-236 that was also photolabeled (11) , the simplest interpretation of these results is that there is an etomidate/azietomidate binding site at a ␤3 ϩ -␣4 Ϫ interface homologous to the etomidate site at the ␤3 ϩ -␣1 Ϫ interfaces in ␣1␤3␥2 GABA A Rs. This conservation of etomidate binding sites between ␣4␤3␦ and ␣1␤3␥2 GABA A Rs is not unexpected, in view of the strong conservation of amino acids in the regions of the ␣4 and ␣1 subunit M1 and M2 helices that contribute to the ␣ Ϫ surface of the etomidate binding sites ( Fig. 9 ) and the fact that etomidate produces similar allosteric modulation in ␣1␤3␦ and ␣1␤3␥2 GABA A Rs (38) .
An 
Several lines of evidence indicate that the ␤3 ϩ -␤3 Ϫ interface is the most likely interface for the site binding etomidate, azietomidate, and R-mTFD-MPAB with high affinity. 1) Photolabeling studies with expressed ␣1␤3 GABA A Rs establish that etomidate, [ 3 H]azietomidate, and [ 3 H]R-mTFD-MPAB all bind with high affinity to the ␤3 ϩ -␤3 Ϫ interface pocket that is present in ␣1␤3 but not in ␣1␤3␥2 GABA A Rs (9, 39) . 2) Examination of the amino acid residues that would contribute to the three alternative binding pockets ( Fig. 9 ) identifies non-conservative substitutions contributing to the (ϩ)-surface of the binding pocket that are expected to prevent the high affinity binding of etomidate in an ␣4 ϩ -␤3 Ϫ or ␦ ϩ -␤3 Ϫ intersubunit pocket. In ␣1␤2/3␥2 GABA A Rs, ␤2/3Asn-265 (␤M2-15Ј) is known to be a major determinant of etomidate binding affinity, and in vitro and in vivo mutational analyses establish that replacement by Ser (␣4M2-15Ј) or Met (␦M2-15Ј) reduces etomidate potency by Ͼ10-fold (12, 13, 40 -42) . Similarly, substitution of ␤3Met-286 by Trp (the ␦ residue in the ␤3Met-286 position) also inhibits the effects of etomidate (40, 43) . Therefore, it is unlikely that etomidate can bind with high affinity at either the ␣4 ϩ -␤3 Ϫ or ␦ ϩ -␤3 Ϫ interface.
Contributions of ␦ Subunit Residues to Etomidate/Barbiturate Binding Sites-In our study, we did not identify any ␦ subunit amino acids photolabeled in an anesthetic-inhibitable manner by [ 3 H]azietomidate or [ 3 H]R-mTFD-MPAB. Based upon sequence analyses of samples containing variable amounts of ␤M3 and ␦M3, any pharmacologically specific photolabeling in ␦M3 is at Ͻ15% the level of ␤M3. It is possible that [ 3 H]azietomidate does bind in a pocket containing ␦M3 residues that is homologous to the ␤ ϩ -␣ Ϫ site without photolabeling any residue in ␦M3, because the pocket would lack the methionine side chains favored by azietomidate's photoreac-␣4␤3␦ GABA A R General Anesthetic Binding Sites DECEMBER 16, 2016 • VOLUME 291 • NUMBER 51 JOURNAL OF BIOLOGICAL CHEMISTRY 26535 tive intermediate. However, it is unlikely that R-mTFD-MPAB binds without photolabeling any residues in its vicinity because both it and S-mTFD-MPPB, another closely related trifluoromethylphenyldiazirine, have been found to react broadly in GABA A Rs with aliphatic as well as aromatic and nucleophilic side chains (11, 36) . ␦ subunit fragmentation with EndoLys-C produced a cleavage 19 amino acids before the NH 2 terminus of ␦M1, which was not close enough to allow high sensitivity sequence analysis. In fact, ␦M1 may contribute to a barbiturate binding site, because studies with receptors containing ␣1, ␤3, and chimeric ␥/␦ subunits indicated that pentobarbital sensitivity determinants were contained within a fragment containing the amino terminus and the first 3 amino acids of ␦M1 (44) . Further studies will be necessary to clarify whether general anesthetics also bind with high affinity in the pocket at the ␤ ϩ -␦ Ϫ interface in the cell line used in this study or at the ␣ ϩ -␦ Ϫ interface in ␤␣␤␣␦ GABA A Rs.
Functional Significance of the Identified Binding Sites-Photolabeling studies provided a first definition of two classes of pharmacologically distinct binding sites for intravenous general anesthetics at subunit interfaces in the ␣1␤3␥2 GABA A R transmembrane domain (8, 11, 36) that overlap with the binding sites for ivermectin (45) . Mutational analyses of the residues identified by photoaffinity labeling as well as neighboring residues in the shared subunit interface pockets have demonstrated their contributions to GABA A R gating and as determinants of anesthetic efficacy (12, 40, 43, 46, 47) . In addition, the capacity of anesthetics to protect against modification of substituted cysteines has expanded the definition of residues contributing to anesthetic binding sites (48, 49) . Mutational analyses will be necessary to determine, for example, whether the ␤ ϩ -␣ Ϫ site and ␤ ϩ -␤ Ϫ sites identified by photoaffinity labeling are equally important for etomidate enhancement of GABA responses in an ␣4␤3␦ GABA A R. However, in view of the difficulty of expressing ␣4␤3␦ GABA A Rs with defined subunit stoichiometry and subunit arrangement, these studies should be carried out using pentameric concatenated receptors.
Experimental Procedures
Materials-[ 3 H]Muscimol (36 Ci/mmol) was from Perkin-Elmer Life Sciences. The detergents n-dodecyl ␤-D-maltopyranoside and CHAPS were from Anatrace-Affymetrix (anagrade quality). R-mTFD-MPAB and [ 3 H]R-mTFD-MPAB (38 Ci/mmol) were prepared previously (50), as was [ 3 H]azietomidate (19.3 Ci/mmol) (39) . Soy bean asolectin, R-etomidate, and GABA were from Sigma. DS2 and alphaxalone were from Tocris. EndoLys-C was from Roche Applied Sciences.
Purification of ␣4␤3␦ GABA A R-A detailed description of the expression and affinity purification of ␣4␤3␦ GABA A Rs will be presented elsewhere. As described previously for ␣1␤3␥2 GABA A Rs (33), a stably transfected, tetracycline-inducible HEK293-TetR cell line expressing human GABA A R subunits ␣4, ␤3 (splice variant 2), and ␦ containing a FLAG tag near its N terminus (between ␦Gly-29 and ␦Asp-30) was induced and grown for 2-3 days, and then membranes were harvested, flashfrozen in liquid N 2 , and stored at Ϫ80°C until use. GABA A Rs were solubilized with 30 mM n-dodecyl ␤-D-maltopyranoside and affinity-purified as described (11) , using a FLAG M2 antibody column. Columns were washed with purification buffer supplemented with 200 M asolectin and 5 mM CHAPS and then eluted with 1.5 mM FLAG peptide in the wash buffer. Aliquots of the eluate fractions were assayed for [ 3 H]muscimol binding, and eluate fractions were flash-frozen in liquid N 2 and stored at Ϫ80°C until use. Membranes harvested from 60 15-cm plates contained ϳ5-10 nmol of [ 3 H]muscimol binding sites (15-20 pmol of sites/mg of membrane protein), and the (8, 9, 11, 36) . The dashed line above each alignment denotes the extent of ␣-helices in the GABA A R structure.
eluate fractions from the purifications used for photolabeling contained 50 -70 nM [ 3 H]muscimol sites. Based upon [ 3 H]muscimol binding, the receptor was purified at 10 -25% yield from the starting membranes. Because the receptor was eluted in the presence of 1.5 mM FLAG peptide, it was not possible to estimate purity in terms of pmol of muscimol binding/mg of protein. Based upon analyses by SDS-PAGE and LC/MS/MS (see "Results"), GABA A R subunits were the dominant polypeptides in the preparation.
Radioligand Binding Assays-[ 3 H]Muscimol binding to purified GABA A R was measured by filtration after precipitation with polyethylene glycol (8) . The total concentration of sites in eluate fractions was determined at 250 nM [ 3 H]muscimol with 1 mM GABA to determine nonspecific binding. Allosteric modulation of 2 nM [ 3 H]muscimol binding was determined as described (9, 11) .
Sequence Numbering-For ␣4, residue 1 is the predicted signal sequence Met; for ␤3, residue 1 is the predicted N terminus of the mature protein (splice variant 1, QSNVD . . . ), with ␤3Met-286 at the 15th position in the M2 helix (M2-15Ј); and for ␦, the numbering begins with the signal sequence Met and excludes the inserted FLAG sequence (DYKDDDDK). The primary structure locations of transmembrane helices M1-M4 in the figures correspond to the extent of the individual ␣-helices in the ␤3 monomeric GABA A R crystal structure (Protein Data Bank code 4COF).
Analysis of the ␣4␤3␦ GABA A R Preparation by LC/MS and N-terminal Sequencing-Three aliquots (24 pmol of [ 3 H]muscimol sites each) of ␣4␤3␦ GABA A R were separated by SDS-PAGE. Based upon Coomassie Blue staining, bands migrating at 78, 72, 62, 58, and 54 kDa were excised. The bands from one lane were submitted to the Harvard Medical School Taplin Mass Spectrometry Facility for reduction and alkylation, in-gel trypsin digestion, and peptide extraction for microcapillary LC/MS/MS analysis. The material from the equivalent gel bands from the other two lanes was eluted and subjected to N-terminal sequence analysis.
GABA A R Photolabeling-Aliquots of purified ␣4␤3␦ GABA A R in elution buffer were photolabeled at analytical or preparative scale (150 -200 l or 1-2 ml of GABA A R per condition, respectively) to characterize photoincorporation at the subunit level or to identify individual photolabeled amino acids by protein microsequencing. Aliquots of [ 3 H]azietomidate or [ 3 H]R-mTFD-MPAB were dried under a gentle argon stream and resuspended with GABA A R solutions for 30 min on ice with gentle vortexing. For preparative photolabeling, non-radioactive drugs were added directly to this resuspension, whereas for analytical photolabeling, drug aliquots were added by the use of a 1-l syringe (Hamilton 86200) to 10 l of purified GABA A R, which was then combined with 90 -150 l of GABA A R equilibrated with radioligand. With the exception of studies with alphaxalone, all photolabeling was carried out in the presence of 300 M GABA. Samples were transferred to 96-well plastic plates or 3.5-cm diameter Petri dishes (Corning catalogue numbers 2797 and 3001) for analytical or preparative scale labeling and irradiated on ice with a 365-nm UV lamp (Spectroline EN-280L) for 30 min at a distance of Ͻ1 cm. Samples were then denatured by mixing 2 parts sample with 1 part SDS-PAGE sample buffer, incubated for ϳ30 min, and fractionated by modified Laemmli SDS-PAGE (11) .
Stock solutions of non-radioactive R-mTFD-MPAB (60 mM), etomidate (60 mM), and alphaxalone (8 mM) were prepared in methanol. For these drugs, all samples during photolabeling contained methanol at a final concentration of 0.5% (v/v). DS2 was prepared at 6 mM in 90% methanol, 10% DMSO. For assays with DS2, samples during photolabeling contained methanol/ DMSO at final concentrations of 0.45%/0.05% (v/v). To minimize losses of hydrophobic drugs due to adsorption on plastic surfaces, glass syringes, capillary pipettes, and vials were used for all material transfers up to the equilibration with the purified GABA A R in detergent/lipid.
After electrophoresis, gels were stained with Coomassie Brilliant Blue. In analytical scale experiments, 3 H incorporation into subunits was determined either by fluorography or by liquid scintillation counting of excised gel bands as described (11) . In preparative scale experiments, material was eluted from the excised stained bands as described (11) To determine the relative binding affinity for anesthetics at the [ 3 H]azietomidate or [ 3 H]R-mTFD-MPAB binding sites, aliquots of ␣4␤3␦ GABA A R were photolabeled in the presence of various concentrations of a drug, and subunit gel slice counts from these aliquots were fit to the equation,
where B(x) represents the gel slice 3 H cpm at total inhibitor concentration x, B 0 is the gel slice 3 H cpm in the absence of competitor, B ns is nonspecific 3 H cpm incorporation in the presence of maximal concentration of a competitor, and IC 50 is the total drug concentration producing 50% inhibition. Data were fit using Sigma Plot version 11.0 (Systat Software, Inc.) with IC 50 and B ns as adjustable parameters; B 0 was fixed at the experimentally observed value. Due to limited quantities of receptor, competition assays were done only once, and the S.E. values given are from the least-squares fits. Proteolysis, Reversed-phase HPLC, and N-terminal Sequence Analysis-Aliquots of labeled subunits isolated from gel bands were digested (2 weeks, 20°C, 0.3-1 units/sample) with EndoLys-C (Roche Applied Science). Digests were fractionated by rpHPLC as described (51) , except that the gradient began at 95% aqueous solvent (0.08% TFA) and 5% organic solvent (60% acetonitrile, 40% isopropyl alcohol, 0.05% TFA) and progressed ␣4␤3␦ GABA A R General Anesthetic Binding Sites DECEMBER 16, 2016 • VOLUME 291 • NUMBER 51
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to 100% organic in 75 min by approximating (in 5-min intervals) the quadratic growth curve, f(x) ϭ 5 ϩ 0.017 ϫ x 2 , where x is time in minutes and f(x) is percentage of organic solvent. The flow rate was 200 l/min, and fractions were collected every 2.5 min, with 10% assayed for 3 H. Fractions of interest were pooled and drop-loaded onto glass fiber filters for N-terminal sequence analysis on an Applied Biosystems Procise 492 protein sequencer modified so that two-thirds of each cycle were injected for PTH-derivative detection and quantification, whereas one-third was collected for scintillation counting. Some digested samples were sequenced without rpHPLC separation by loading them onto Applied Biosystems ProSorb TM PVDF filters by diluting the samples 10-fold into 0.1% TFA. The pmol of PTHderivatives detected were calculated by using rpHPLC peak heights at 269 nm compared with a standard injection.
Photolabeling in ␣4M1 or ␣4M3 was determined by sequencing appropriate rpHPLC fractions from digests of the 72 kDa gel band. Labeling in ␤3M1 and ␤3M3 was identified by sequencing fractions from the 58/62 kDa gel bands. In preliminary studies, we established that that fragments containing ␦M1 and ␦M3 were present at the highest level in the fractions containing ␤M3 from the 58/62 kDa gel band, where they were present at ϳ50% the level of the ␤M3 fragment. The ␦M3 fragment was present in the equivalent fractions from the 54 kDa gel band at ϳ200% the level of the ␤M3 fragment. The N termini of ␤M3 (␤3Ala-280) and ␦M3 (␦Ala-309) were each at the first cycle of Edman degradation. However, comparison of 3 H release profiles and relative amounts of ␤M3 and ␦M3 during sequence analyses of fractions from the 54 and 58/62 kDa gel bands established that the anesthetic-inhibitable peaks of 3 H release originated from residues in ␤M3 rather than ␦M3. Sequencing through ␦M1 began only after 19 cycles of Edman degradation, at which point PTH-derivative and 3 H releases were too low to allow characterization of photolabeling in ␦M1.
The detected sequences were quantitated by fitting the background-subtracted pmol of the detected peptide to the equation,
where M(x) represents the pmol in cycle x, I 0 is the initial amount of the peptide, and R is the repetitive yield. Cys, Trp, Ser, and His were omitted from the fits due to known problems with their quantitations. The 3 H incorporation E(x), the efficiency of photolabeling (in cpm/pmol) of the amino acid in cycle x, was calculated by the following equation. 
